Evaluating orelabrutinib as a novel treatment option for relapsed/refractory chronic lymphocytic leukemia in China-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Evaluating orelabrutinib as a novel treatment option for relapsed/refractory chronic lymphocytic leukemia in China

Published:2022-11-11 Issue:18 Volume:23 Page:1979-1986
ISSN:1465-6566
Container-title:Expert Opinion on Pharmacotherapy
language:en
Short-container-title:Expert Opinion on Pharmacotherapy

Author:

Gu Danling¹²³^ORCID,Li Jianyong¹²³,Miao Yi¹²³

Affiliation:

1. Pukou CLL Center, Pukou Division of Jiangsu Province Hospital, Nanjing, Jiangsu, China

2. Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, Jiangsu, China

3. Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing, Jiangsu, China

Funder

the National Nature Science Foundation of China

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Pharmacology,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/14656566.2022.2144218

Reference39 articles.

1. Chronic Lymphocytic Leukemia

2. Chronic lymphocytic leukaemia

3. Small Lymphocytic Lymphoma and Chronic Lymphocytic Leukemia

4. Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial

5. First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Challenges associated with the use of Bruton's tyrosine kinase inhibitors: A life‑saving therapy for chronic lymphocytic leukemia (Review);World Academy of Sciences Journal;2024-04-02

2. A Comprehensive Review of Small-Molecule Inhibitors Targeting Bruton Tyrosine Kinase: Synthetic Approaches and Clinical Applications;Molecules;2023-12-11

3. Synthesis and application of small molecules approved for the treatment of lymphoma;European Journal of Medicinal Chemistry;2023-12

4. Cost–effectiveness of BTK inhibitors vs bendamustine and rituximab in chronic lymphocytic leukemia patients;Future Oncology;2023-12

5. Clinical Research Progress of BTK Inhibitors in the Treatment of Autoimmune Diseases;Current Topics in Medicinal Chemistry;2023-11

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3